172PD Final analysis: Phase II trial of...

Annals of Oncology 2016 / 12 Vol. 27; Iss. suppl_9

172PD Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment

Ando, T., Yuki, S., Nakatsumi, H., Muranaka, T., Hosokawa, A., Tsuji, Y., Nakamura, M., Muto, O., Sasaki, T., Iwanaga, I., Hatanaka, K., Sato, A., Eto, K., Furukawa, K., Tateyama, M., Takahashi, Y., S
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
27
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw581.004
Date:
December, 2016
File:
PDF, 69 KB
2016
Conversion to is in progress
Conversion to is failed